SEC Form SC 13G/A filed by Nkarta Inc. (Amendment)
$NKTX
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/15/2025 | Outperform → Mkt Perform | William Blair | |
| 10/9/2024 | $14.00 | Buy | Rodman & Renshaw |
| 8/14/2024 | $16.00 | Outperform → Strong Buy | Raymond James |
| 3/22/2024 | $13.00 → $16.00 | Strong Buy → Outperform | Raymond James |
| 12/22/2022 | Outperform → Perform | Oppenheimer | |
| 10/10/2022 | $25.00 | Buy | Canaccord Genuity |
| 7/28/2022 | $26.00 | Buy | Needham |
| 7/18/2022 | $30.00 | Outperform | SVB Leerink |
4 - Nkarta, Inc. (0001787400) (Issuer)
4 - Nkarta, Inc. (0001787400) (Issuer)
4 - Nkarta, Inc. (0001787400) (Issuer)
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the Evercore 8th Annual Healthcare Conference on Thursday in Miami. Evercore 8th Annual Healthcare ConferenceDecember 4, 202510:50 a.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkarta's website, and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-
Enrollment now underway in second dose-escalation cohort Deep B-cell depletion observed in all patients treated to date who received NKX019 with lymphodepletion using fludarabine and cyclophosphamide versus partial B-cell depletion in patients receiving only cyclophosphamideEnrollment streamlined across Ntrust-1 and Ntrust-2 under a combined independent Data Safety Monitoring Board (iDSMB) to guide dose escalation Initial data for NKX019 in multiple autoimmune indications expected to be presented at a medical conference in 2026Cash balance of $316.5 million on September 30, 2025, including cash, cash equivalents, and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Ca
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conferences next month: Stifel 2025 Healthcare ConferenceNovember 12, 202510:40 a.m. ET – fireside chat TD Cowen's Immunology & Inflammation SummitNovember 13, 20255 p.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkarta's website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is a clinical-stage biotechnology company a
S-8 - Nkarta, Inc. (0001787400) (Filer)
SCHEDULE 13D/A - Nkarta, Inc. (0001787400) (Subject)
SCHEDULE 13G/A - Nkarta, Inc. (0001787400) (Subject)
4 - Nkarta, Inc. (0001787400) (Issuer)
4 - Nkarta, Inc. (0001787400) (Issuer)
William Blair downgraded Nkarta from Outperform to Mkt Perform
Rodman & Renshaw initiated coverage of Nkarta with a rating of Buy and set a new price target of $14.00
Raymond James upgraded Nkarta from Outperform to Strong Buy and set a new price target of $16.00
SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced the appointment of Shawn Rose, M.D. Ph.D., as its next Chief Medical Officer (CMO) and Head of Research and Development (R&D) starting on June 23, 2025. He replaces David R. Shook, M.D., who will be stepping down from the role to pursue other opportunities in the oncology space. Dr. Rose has dedicated his career to immunology translational medicine and advancing new treatment options for autoimmune patients. In various leadership roles, he has brought
Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded to include primary membranous nephropathy cohort Lymphodepletion regimen modified across platform to include fludarabine and cyclophosphamide with cyclophosphamide alone remaining available for eligible patients Initial data for NKX019 in multiple autoimmune indications expected in second half of 2025 Cash balance of $351.9 million on March 31, 2025, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., May 14, 2025
SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced changes to its leadership team. Nadir Mahmood, Ph.D., will join Nkarta as President this month, sharing executive leadership responsibilities with Paul J. Hastings, who continues in his role as Chief Executive Officer. Additionally, Nkarta has broadened the role of David R. Shook, M.D., to Chief Medical Officer, Head of Research & Development. Drs. Mahmood and Shook will both report to Mr. Hastings. "This new leadership structure enables Nkarta to meet this transformative moment for cell therapy as
New pipeline program builds on academic studies of durable, drug-free remissions in patients with autoimmune disease after CD19-targeted cell therapy NKX019, an allogeneic CAR NK cell therapy targeting CD19+ B cells, could modify refractory autoimmune disease while maintaining NK-driven safety profile Off-the-shelf accessibility and proprietary engineering could eliminate burdens of autologous products and may enable differentiating conditioning regimen Resource prioritization and cost reductions expected to extend cash runway by one year into 2026 to support important clinical data readouts in 2024 Estimated cash and cash equivalents of $278.4 mil
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that it will host a conference call on Tuesday, October 17, 2023 at 8:00 a.m. ET to discuss clinical program updates and organizational cost measures and resource prioritization to support clinical milestones. Conference Call and WebcastTo access the conference call, please register through this link: https://nkarta-business-update.open-exchange.net/registration A replay will be archived on the Investors section of Nkarta's website, www.nkartatx.com, for approximately four weeks. About NkartaNkart
Encouraging antileukemic activity seen with NKX101 in patients with AML, including several with high-risk features, using a modified lymphodepletion incorporating Ara-C (cytarabine)In patients with r/r AML treated with a three-dose regimen of NKX101 at 1.5 billion cells per dose after fludarabine/Ara-C for lymphodepletion, n=6 4 of 6 patients achieved complete response (67% CR/CRi, 50% CR rate)2 CRs with MRD negativity1 patient deepened response to MRD negative CRi with additional cycles NKX101 was well tolerated across dose-levels and lymphodepletion regimensExpansion cohort incorporating Ara-C based lymphodepletion expected to be the basis of NKX101 development moving forwardUpdated clinic
SC 13G - Nkarta, Inc. (0001787400) (Subject)
SC 13G/A - Nkarta, Inc. (0001787400) (Subject)
SC 13G/A - Nkarta, Inc. (0001787400) (Subject)